Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.49 |
| ▸ | PGR | P06401 | 3/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107697 | 0.86 | GCK (0.57) | GCKCA1CA2PTGS2ALDH1A1 | |
| SCHEMBL1799919 | 0.85 | SRD5A2 (0.54) | GCKPTGS2RAB9AALDH1A1KAT6A | |
| SCHEMBL883130 | 0.82 | TNKS (0.60) | PGRCA1CA2RAB9AMAPT | |
| SCHEMBL14018389 | 0.82 | PGR (0.60) | PGRPTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2651155 | 0.80 | POLB (0.61) | CA1CA2PTGS2ALDH1A1GAA | |
| SCHEMBL14018981 | 0.80 | NR1H2 (0.55) | GCKPGRPTGS2LMNAKAT6A | |
| SCHEMBL2345466 | 0.79 | CA12 (0.59) | CA1CA2PTGS2LMNAPOLB | |
| SCHEMBL31610890 | 0.79 | CA12 (0.59) | CA1CA2PTGS2LMNAPOLB | |
| SCHEMBL8569015 | 0.79 | CA1 (0.55) | CA1CA2RAB9AMAPTALDH1A1 | |
| SCHEMBL27480274 | 0.79 | HSD17B1 (0.59) | CA1CA2RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1861360-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101808-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | HRH3, HCRTR1, HRH4 | GCK 1641/4885PGR 908/4885STS 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.